Brenda Eap, PhD

Many people can’t afford to miss work to join a clinical trial — even though participation strengthens public health. Would you enroll in a baseline clinical trial if your employer paid you?

We’re opening H‑SPAN Arizona with the foundation that drives everything in longevity: cutting‑edge academic research featuring: Dr. George Sutphin (@senmorteco) (Associate Professor, @UAZBIO5, University of Arizona) — advancing genetic and pharmacological approaches to extend lifespan and healthspan. Dr. Noah Snyder‑Mackler (Professor, School of Life Sciences and Center for Evolution and Medicine, @ASU) — uncovering the molecular and environmental drivers of aging using multi‑omics and primate models. Dr. Bonnie LaFleur (Director, Health Outcomes & PharmacoEconomics Center, University of Arizona @uazresearch) — pioneering biostatistical and biomarker frameworks that translate aging science into precision‑health applications. Together, they’ll highlight the newest directions emerging from Arizona’s academic labs — from cellular mechanisms to translational pathways and set the scientific foundation for the biotech, innovation, and policy discussions that follow throughout the day. Starting with the science is intentional. It grounds the event in rigor, showcases Arizona’s growing leadership in geroscience, and spotlights the researchers pushing the field forward. More speaker highlights coming soon as we count down to H‑SPAN Arizona: partiful.com/e/trmLrsuHDWm4…. @AZTechWeek

It’s been a blast putting this event together. Really looking forward to the conversations!

Congratulations to Jim O’Neill on his nomination to serve as Director of the National Science Foundation. NSF’s commitment to basic science is essential for advancing the frontiers of discovery, including the biology of aging. A number of early‑career trainees have earned prestigious NSF fellowships to pursue fundamental aging‑research projects, and several foundational studies in the field receive NSF support each year. A4LI looks forward to continued progress in uncovering the mechanisms that drive healthy longevity.

@celinehalioua Omg! I took this picture on Monday thinking it had been up there for a while now and wondered how I could have missed this. Congrats!!

we have taken over the SF mint

@SenateAging Committee’s From Regulator to Roadblock: How FDA Bureaucracy Stifles Innovation hearing underscored a broader truth that spans both rare diseases and aging‑related conditions: when FDA standards become unpredictable, entire patient populations—small and large lose access to timely, safe innovation. Rare‑disease advocates spoke powerfully about navigating a system built for large trials and long timelines, but the same structural barriers now affect aging‑related diseases that impact tens of millions. Whether the population is tiny or enormous, the core issue is the same: regulatory uncertainty is slowing progress, pushing trials and manufacturing overseas, and weakening America’s leadership in biomedical innovation. That’s why we developed the Advanced Approval Pathway for Longevity Medicine in 2023, building on the strengths of accelerated approval and applying them to longevity therapeutics, where early signals, biomarkers, and real‑world evidence are essential. The hearing made clear that modernized pathways are no longer optional—they’re necessary if the U.S. wants to remain competitive and responsive to patient needs. We also appreciate @SenRonJohnson’s call for a Right to Try 2.0 and the Committee’s focus on keeping clinical trials and biomanufacturing in the U.S. The overlap between rare disease and aging is simple: both communities deserve a system that moves at the speed of science, not bureaucracy. Listen to the hearing here: aging.senate.gov/hearings/from-…

You are invited to join the Buck for virtual screening this Saturday of Forever Young, an award-winning documentary exploring the science of aging and the future of longevity research. Q&A with Buck's CEO and Movie Director following. 👉 Reserve Your Spot: kinema.com/events/Forever…

RT @theA4LI: @ARPA_H has committed $144 million to PROactive Solutions for Prolonging Resilience (PROSPR) Program to accelerate the develop…

Loyal (@loyalfordogs) is on track to launch the first FDA‑approved lifespan‑extension drug, LOY‑002, an oral, once‑daily pill that targets metabolic dysfunction — a fundamental mechanism of aging and is designed specifically for senior dogs. The fully enrolled STAY trial is Loyal’s pivotal effectiveness study under the FDA Center for Veterinary Medicine’s expanded conditional approval pathway. Completion of STAY, expected in 2029, would position LOY‑002 for full market approval. Learn more Loyal and the STAY study here: loyal.com We’re excited to have Hubert Chen, Chief R&D Officer at Loyal, join us at the H‑SPAN Summit this summer to share updates on LOY‑002 and the company’s pioneering work in veterinary longevity therapeutics. We applaud Loyal’s team and CEO Celine Halioua (@celinehalioua) for pushing the boundaries of what's possible in longevity science. Loyal’s presence alongside human‑focused longevity companies underscores just how dynamic and interconnected this moment is for the longevity science ecosystem! Learn more about our H-SPAN Summit here: a4li.org/h-span-summit-…

Within a year, @Gordianbio went from not working in obesity to running in vivo screens in visceral adipose tissue and signing a collaboration with Pfizer. @BradLoncar stopped by the lab to hear about it. There are thousands of GWAS hits that correlate with body weight and other targets with human evidence, but the bottleneck is figuring out which of those are interesting as drug targets, with causal potential, in a relevant biological environment. Gordian solves that. We use AAV to deliver different payloads into a tissue so you get a mosaic where individual cells are perturbed by different targets. Then we read it out with single-cell transcriptomics to assess what changed after treatment. Does targeting this gene do what you'd expect, or does it get overruled by inflammatory signaling or systemic metabolism? You can rank hundreds of targets for causal signal in one experiment. Brad asked great questions about where in vivo models still matter and where they don't. Worth a watch if you're thinking about the next wave of obesity target discovery beyond GLP-1s.

NEW EPISODE dropped today! XPRIZE Healthspan Exec Dir Jamie Justice joins Brianna Stubbs to discuss $101M race to restore 10 yrs of muscle, cognitive, and immune function within a single year, shifting medicine from treating isolated diseases to scaling human healthspan globally.

BioAge Labs (@bioagelabs) recently announced positive interim results for BGE‑102, its oral, brain‑penetrant NLRP3 inhibitor targeting a pathway central to age‑related inflammation and implicated in cardiovascular disease, neurodegeneration, and metabolic disorders. Early data show strong target engagement and meaningful reductions in inflammatory biomarkers including hsCRP, IL-6, and IL-1β. The company also plans to expand BGE‑102 into diabetic macular edema (DME) later this year, reflecting growing evidence that NLRP3‑driven inflammation plays a key role in retinal disease. Read more about it here: ir.bioagelabs.com/news-releases/… We’re excited to have Dr. Eric Morgen (@eric_k_morgen) from BioAge Labs at our H‑SPAN Summit this summer to share updates on BGE‑102 and to join the discussion on better regulatory frameworks to incentivize multi‑indication, multimorbidity‑focused drug development — essential for accelerating progress toward healthier, longer lives. Get your ticket today: a4li.org/h-span-summit-…

A4LI is pleased to announce the appointment of Eric Morgen, MD (@eric_k_morgen | COO of @bioagelabs) and Karl Pfleger, PhD (@KarlPfleger | Founder of AgingBiotech.info) to our Board of Directors. From the beginning, both have played a pivotal role in guiding A4LI’s strategic direction and helping us build momentum as an early-stage advocacy organization in a rapidly evolving field. We are grateful for their continued leadership across the longevity ecosystem and invite you to join us in welcoming them to the Board! Full Press Release here: a4li.org/wp-content/upl…

Rubedo Life Sciences (@LifeRubedo) has reached an exciting milestone with the launch of its Phase 1 clinical trial for RLS‑1496, a first‑in‑class GPX4 modulator designed to selectively target pathologic senescent cells, a key driver of inflammaging and chronic age-related diseases. Developed using Rubedo’s ALEMBIC™ platform, RLS‑1496 is a disease‑altering small molecule now being evaluated for the safety and clinical effects of single and multiple topical doses in adults with mild to moderate plaque psoriasis, skin aging, and other inflammatory skin conditions including atopic dermatitis, vitiligo, rosacea, alopecia areata, and scleroderma. This study represents the first GPX4 modulator to enter human testing, positioning Rubedo at the forefront of senescence‑targeting therapeutics and longevity science. Public information about the trial, including design and eligibility criteria, is available via ClinicalTrials.gov: clinicaltrials.gov/study/NCT07340… We’re thrilled that Rubedo Life Sciences will be joining us at the H‑SPAN Summit this summer, where leaders across science, policy, and industry will explore how innovations like RLS‑1496 can accelerate progress toward healthier, longer lives. Get your tickets today: a4li.org/h-span-summit-…

Incredible. Something i’ve thought about doing for a long time too and definitely going to help people understand the complexity of the field. Can’t wait to play!!! Thanks @agingdoc1!

I built two free web games about turning aging biology into longevity therapeutics.🚀 Play and challenge a friend: 1: longevity-revolution.pages.dev 2: longevity-revolution-2.pages.dev Orgs linked inside, incl. @theA4LI @AFARorg and many more! If you care about translation, please repost. 🧪

@Dr_KevinTran Hey that’s BrainBit!!!

Your brain can change in 2–3 weeks. Not motivation, EEG proves it. Like the gym builds muscle, brain training builds neural pathways. 8–15 min a day. 2–3x a week. Week 3: change. Week 4: it sticks. No pills. No drugs. Just neuroplasticity.

@SchurmanCharlie Congratulations, Charlie!!!

Hey, it me!!

@Dr_KevinTran Awww you got Paola from Sens.ai!!!

Same brain tech. Different Hz. Totally different effect. Hit the wrong frequency? Foggy. Hit your frequency? Laser-sharp. Your brain has a signature. Generic neurotech ignores it.

This morning, the Senate Health, Education, Labor and Pension (@GOPHELP) Committee held a hearing on “Modernizing the National Institutes of Health: Faster Discoveries, More Cures” with expert witness and NIH Director, Dr. Jay Bhattacharya (@NIHDirector_Jay). We appreciate Congress’ focus on ensuring that @NIH grant funding reaches institutions across all states and supports continued U.S. leadership in biomedical research. We also welcome Dr. Bhattacharya’s emphasis on investing in research that keeps Americans healthy and strengthening support for early career trainees — essential steps in advancing research toward closing the healthspan and lifespan gap. It’s worth underscoring that, according to NIH RePORTER, all 50 states are conducting aging biology research. We highlight this in our conversations with Members of Congress and their staff as we work to bring additional research dollars to the National Institute on Aging (@NIHAging) . If you’re building or researching in this space, we hope you’ll join us at the H SPAN Summit this summer. Early bird pricing ends this week. help.senate.gov/hearings/moder…

More people should phrase the goal as curing molecular pathologies of aging rather than extending spans (lifespan, healthspan). Molecular pathology is inherently worthy of fixing on its own terms. We don't fix it just because it's a subgoal required for longer spans (longevity).